Samuel Isaly Says He Is Fond of Regeneron Pharmaceuticals Inc (REGN) & InterMune Inc (ITMN)

Samuel Isaly‘s Orbimed Advisors is one of the largest hedge funds focused almost entirely on the healthcare sector. In a recent intervention on CNBC, Mr. Isaly presented his bullish case on two stocks, which, surprisingly, aren’t among the top five holdings in Orbimed’s latest 13F. These companies are Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and InterMune Inc (NASDAQ:ITMN), both stocks of which experienced significant growth since the beginning of the year, while Intermune more than doubled within one day.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals Inc (NASDAQ:REGN), Mr. Isaly says that he finds this company the most attractive, mainly because of its “multi-billion dollar product for treatment of blindness in older people.” The product, called EYLEA® has recently been accepted by the FDA for the supplemental Biologics License Application for the treatment of Macular Edema Following Branch Retinal Vein Occlusion, the company said.  Moreover, Bayer HealthCare’s Japanese subsidiary, Bayer Yakuhin has filed an application for marketing authorization of the product with the Japanese Ministry of Health, Labour and Welfare, Regeneron said in another statement.

Isaly holds 738,800 shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN), according to Orbimed’s latest 13F filing. The reported value of the position amounts to over $203 million, which makes it the eight largest holding (3% of the equity portfolio). Orbimed has upped the position by 44% during the last quarter of 2013, and has been adding more shares to the holding over the past couple of years. Columbus Circle Investors, led by Donald Chiboucis, is also a shareholder of Regeneron, owning 410,800 shares. However, while Columbus inched down the holding, Jerome Pfund and Jerome Pfund Sectoral Asset Management, apparently aggree with Isaly, and boosted its holding by over 50% to 276,000.

Intermune

In InterMune Inc (NASDAQ:ITMN), Mr. Isaly surged its holding by some 170% and currently holds around 7.7 million shares. As it was mentioned above, this has been a great bet for Orbimed, as the stock of InterMune Inc (NASDAQ:ITMN) has managed to double since the beginning of the year, which values the holding at $242.5 million, at the current price. However, Mr. Isaly considers that this is not the stopping point for InterMune Inc (NASDAQ:ITMN) and that the stock price is poised to go even higher.

The explanation for this growth lie in the announcement made by InterMune Inc (NASDAQ:ITMN) at the end of February, which presented successful results from a Phase 3 trial of a drug called pirfenidone in patients with idiopathic pulmonary fibrosis. The drug managed to reduce the progression of the disease. In this way, the drug met the primary and secondary endpoints.

Aside from Orbimed, which owns one of the largest long positions in the company, William Leland Edwards‘ Palo Alto Investors also reported a stake in InterMune Inc (NASDAQ:ITMN), which amasses more than 3.8 million shares.

The full video of Mr. Isaly’s discussion on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Intermune can be watched below:

Disclosure: none

Recommended Reading:

Luxor Capital Group Raises Stake and Goes Activist on BJ’s Restaurants, Inc. (BJRI)

George Soros and Jeff Altman Are Both Betting On These Six Stocks

Warren Buffett and Lou Simpson Are Bullish On These Stocks

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!